Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics Inc (TRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
2 Breakout Growth Stocks With 200% Upside Potential

The success of their pipelines could change the narrative for these emerging biotech companies.

ANRO : 4.31 (+5.38%)
TRVI : 2.91 (+6.59%)
$SPX : 5,969.34 (+0.35%)
5 Biotech Stocks Under $10 With Multibagger Potential

As the biotech industry continues to redefine the healthcare landscape, here are five penny biotech stocks poised for meteoric growth in this evolving industry.

ADCT : 1.9900 (+2.58%)
$SPX : 5,969.34 (+0.35%)
RZLT : 4.91 (+1.03%)
TRVI : 2.91 (+6.59%)
ELEV : 0.6034 (-0.30%)
CRDL : 1.6200 (+2.53%)
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvioâ„¢ in Prurigo Nodularis

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.91 (+6.59%)
Trevi Therapeutics to Participate in Upcoming September Events

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.91 (+6.59%)
Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.91 (+6.59%)
Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.91 (+6.59%)
Trevi Therapeutics to Participate in Upcoming August Events

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.91 (+6.59%)
Trevi Therapeutics to Participate in Upcoming July Investor Events

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.91 (+6.59%)
Trevi Therapeutics to Participate in Upcoming June Conferences

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.91 (+6.59%)
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.91 (+6.59%)

Barchart Exclusives

1 Cathie Wood Stock to Buy Now and Hold for Long-Term Upside
This Cathie Wood stock just received an upgrade from an analyst who recommends it for long-term investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar